{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:12:19Z","timestamp":1761959539680,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T00:00:00Z","timestamp":1420588800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/j.lrr.2014.09.004","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T12:39:18Z","timestamp":1421325558000},"page":"15-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts"],"prefix":"10.1016","volume":"4","author":[{"given":"R\u00e9gis T.","family":"Costello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se Le","family":"Treut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-1124","authenticated-orcid":false,"given":"Delphine","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"S\u00e9bahoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lrr.2014.09.004_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2014.09.004_bib2","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/ijc.25635","article-title":"Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation","volume":"128","author":"Schmiedel","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lrr.2014.09.004_bib3","doi-asserted-by":"crossref","first-page":"421702","DOI":"10.1155\/2012\/421702","article-title":"Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications","volume":"2012","author":"Farnault","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.lrr.2014.09.004_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fimmu.2014.00087","article-title":"Human NK cells: from surface receptors to the therapy of leukemias and solid tumors","volume":"5","author":"Moretta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.lrr.2014.09.004_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/asheducation-2013.1.511","article-title":"Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes","volume":"2013","author":"Saunthararajah","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.lrr.2014.09.004_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.lrr.2014.09.004_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.lrr.2014.09.004_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.23368","article-title":"Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.lrr.2014.09.004_bib9","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048915000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048915000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:07:32Z","timestamp":1761959252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048915000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"alternative-id":["S2213048915000023"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2014.09.004","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2014.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}